In early clinical development (CT I), the main intention is to deliver the needed amounts of material immediately and in reproducible high-quality.In November 2016, the FDA posted the steerage Agreement Manufacturing Preparations for Medication: Good quality Agreements, which describes the agency’s present anticipations for companies that outsour